Dose-Ranging Study in Younger Adult and Elderly Patients of ORG 9487, a New, Rapid-Onset, Short-Duration Muscle Relaxant

Kahwaji, Raymond; Bevan, David R.; Bikhazi, George B.; Shanks, Colin A.; Fragen, Robert J.; DYCK, BARRY; Angst, Martin S.; Matteo, Richard S.

doi:10.1097/00132586-199804000-00017

Cited by 6 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 Other investigators reported a mean block of 57-91% 60 seconds after the same dose. 7,8,22,24 As with all other nondepolarizing agents, the time to peak effect decreases with increasing doses of rapacuronium up to 1.5-2.0 mg/kg. With higher doses the onset time does not decrease, but duration of action increases substantially.…”

Section: Onset Of Blockmentioning

confidence: 95%

“…17 No significant differences were observed between adults (18-64 yrs) and the elderly with respect to time to peak effect, maximum block, percentage block at 60 seconds, or recovery times after doses of 0.5-2.5 mg/kg doses. 24 Similar to succinylcholine 1.0 mg/kg, rapacuronium 1.5-2.0 mg/kg provides good to excellent intubating conditions within 60-90 seconds in adults. 24,27 A dose of 1-2 mg/kg provides good to excellent intubating conditions 1120…”

Section: Onset Of Blockmentioning

confidence: 99%

“…Several studies evaluated the drug's onset of neuromuscular block in adults (Table 1). [7][8][9][16][17][18][19][20][21][22][23][24][25][26][27][28] Onset time, defined as the interval between administration and maximum depression of muscle twitch, after a dose of 1.5-2.0 mg/kg is similar to that of succinylcholine but significantly faster than those after intubating doses of vecuronium, mivacurium, atracurium, or rocuronium. 7, 18-21, 27, 29 Peak effect after a dose of 1.5 mg/kg occurs between 60 and 114 seconds, most commonly around 70-90 seconds.…”

Section: Onset Of Blockmentioning

confidence: 99%

“…7,8,[18][19][20][21][22][23]27 Differences in reported mean times to peak effect probably are due to variations in anesthetic techniques, methods of measuring muscle function, and whether the dose was based on the active moiety or bromide salt. 24 A 1.5-mg/kg dose of rapacuronium is equivalent to 1.7 mg/kg of its bromide salt. 24 In our experience, mean times to peak effect of 1.5 and 2.0 mg/kg in adults are 117 and 88 seconds, respectively (unpublished data).…”

Section: Onset Of Blockmentioning

confidence: 99%

“…24 A 1.5-mg/kg dose of rapacuronium is equivalent to 1.7 mg/kg of its bromide salt. 24 In our experience, mean times to peak effect of 1.5 and 2.0 mg/kg in adults are 117 and 88 seconds, respectively (unpublished data).…”

Section: Onset Of Blockmentioning

confidence: 99%

See 4 more Smart Citations

Clinical Pharmacology of Rapacuronium Bromide, a New Short‐Acting Neuromuscular Blocking Agent

1999

View full text Add to dashboard Cite

Rapacuronium is a new steroidal, nondepolarizing, neuromuscular blocking agent. It appears to be the least potent of all available nondepolarizing muscle relaxants. Its onset of action resembles that of succinylcholine, and its recovery times are shorter than those of other nondepolarizing agents. The clinical duration of rapacuronium can be shortened significantly with early (2 min) administration of neostigmine, which may be beneficial in patients with difficult airway or failed intubation. Rapacuronium appears to be free of significant cardiovascular complications.

show abstract

Section: Onset Of Blockmentioning

confidence: 95%

Section: Onset Of Blockmentioning

confidence: 99%

Section: Onset Of Blockmentioning

confidence: 99%

Section: Onset Of Blockmentioning

confidence: 99%

Section: Onset Of Blockmentioning

confidence: 99%

See 3 more Smart Citations

Clinical Pharmacology of Rapacuronium Bromide, a New Short‐Acting Neuromuscular Blocking Agent

1999

View full text Add to dashboard Cite

show abstract

Comparison of recovery following rapacuronium, with and without neostigmine, and succinylcholine

Hayes¹,

Breslin²,

Reid³

et al. 2000

Anaesthesia

View full text Add to dashboard Cite

show abstract

Rapacuronium: clinical pharmacology

Mirakhur

McCourt

2001

Eur J Anaesthesiol

View full text Add to dashboard Cite

Summary The need for a rapid‐acting non‐depolarizing neuromuscular blocking agent with a short duration of action resulted in the synthesis of rapacuronium. The onset of maximum block with rapacuronium occurs in 60–90 s with doses of 1.5–2.5 mg kg−1 with a duration of clinical relaxation of 15–30 min. Rapacuronium provides clinically acceptable intubating conditions in 60 s in a majority of patients with these doses, although the conditions are somewhat inferior to those obtained with succinylcholine in lightly anaesthetized patients, such as those undergoing a rapid‐sequence induction. The main drawbacks of rapacuronium are the occurrence of dose‐related pulmonary side‐effects (increased airway pressure and/or overt bronchospasm) and hypotension and tachycardia. The cause of pulmonary side‐effects is not certain but these have been serious enough to make its worldwide introduction doubtful.

show abstract

Dose-Ranging Study in Younger Adult and Elderly Patients of ORG 9487, a New, Rapid-Onset, Short-Duration Muscle Relaxant

Cited by 6 publications

References 0 publications

Clinical Pharmacology of Rapacuronium Bromide, a New Short‐Acting Neuromuscular Blocking Agent

Clinical Pharmacology of Rapacuronium Bromide, a New Short‐Acting Neuromuscular Blocking Agent

Comparison of recovery following rapacuronium, with and without neostigmine, and succinylcholine

Rapacuronium: clinical pharmacology

Contact Info

Product

Resources

About